Only Product of its Kind in Europe to Offer up to Six Months of Pain Relief
in OA Knee Pain
CAMBRIDGE, Mass., Dec. 19 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ) announced today that it has been granted European approval through a CE mark for Synvisc-One(TM), the single treatment of Synvisc(R) (hylan G-F 20) that has been shown in the European Union to provide up to six months of proven pain relief from osteoarthritis (OA) of the knee. Synvisc-One is now the only viscosupplementation product available in Europe that is labeled to provide this long-term duration of pain relief from a single injection.
Genzyme believes that Synvisc-One will simplify osteoarthritis pain management and provide added patient convenience, while reducing the overall cost of therapy associated with multiple injections and offering a treatment option that will expand the benefits of viscosupplementation to a broader number of patients.
"The European approval of Synvisc-One is based on positive clinical data which demonstrated that combining three doses of Synvisc in a single treatment is safe and effective in providing pain relief for up to six months in patients with knee osteoarthritis," stated Ann Merrifield, president of Genzyme Biosurgery, the business unit of Genzyme Corp. that manufactures and markets Synvisc. "Delivering the benefits of Synvisc through one treatment rather than three will provide additional options for physicians and their patients to reduce the cost and burden of multiple injections."
Genzyme will also pursue marketing approvals for Synvisc-One in wider geographies in Canada, Asia and Latin America based on the European CE mark approval.
Synvisc is currently deliver
|SOURCE Genzyme Corp.|
Copyright©2007 PR Newswire.
All rights reserved